said oligonucleotide selected from the group consisting of oligonucleotides consisting of the sequence:

AGGCCATGGCAGGTTTCCTG (SEQ ID NO: 1);
AACTGAAGATCTACAAAAGA (SEQ ID NO: 2);
ACCAAGGTTCTGGAAAGAGA (SEQ ID NO: 3);
TGTAGGTCACCTGAGTGTGA (SEQ ID NO: 4);
GCTGCACCCAGGGGATCCAT (SEQ ID NO: 5);
TCTCGTAGTTGCTTCTGCTG (SEQ ID NO: 6);
GAGCGAGGCCGCAGCGTCTC (SEQ ID NO: 7);
ATCAGCCAGAACCATCACTC (SEQ ID NO: 8);
ACCTGTACCCTATAAGTGGT (SEQ ID NO: 9);
GATAACTTACCTGGAGAGGC (SEQ ID NO: 10);
TTAGGGTTGGACATGATATC (SEQ ID NO: 11);
CCCACTCCTGCAGGGCAGTG (SEQ ID NO: 12);
GGGTCTTCACCACTGGAGAG (SEQ ID NO: 13);
AGTGAAAAGGCTGACCTGAA (SEQ ID NO: 14);
TGGATGCCCGTGACACTGGG (SEQ ID NO: 15);
GCCGGGCCCAGGGGATCCAT (SEQ ID NO: 16);
CACCCAGATCCAGCGTCCCA (SEQ ID NO: 17);
ATCTCCTGACCTTGTGATCC (SEQ ID NO: 18);
GATCTCCTGACCTAGGAAGA (SEQ ID NO: 19);
TTCTCACTCAGTTGGCCCAT (SEQ ID NO: 20);
CCAACCACCACACCTGTCAT (SEQ ID NO: 21);
GGACGAGTAACAGCTGGATT (SEQ ID NO: 22);
GCTTGGCTGCACCCAGGGGATC (SEQ ID NO: 23);
CTCTGCCGCTCCTGGACACTGCTGC (SEQ ID NO: 24);

and continuous 15 or 18 nucleotide fragments of the sequences listed above in an amount effective to treat said cancer.

Please amend Claim 16 as follows:

~~16.~~ (Amended) A method of treating a subject afflicted with cancer, comprising administering to said subject a vector that comprises and expresses an exogenous nucleic acid encoding an antisense oligonucleotide that hybridizes to an endogenous nucleic acid that encodes a fucosyltransferase, wherein said fucosyltransferase is selected from the group consisting of FUT3 and FUT6 and wherein said nucleic acid is selected from the group consisting of:

AGGCCATGGCAGGTTTCCTG (SEQ ID NO: 1);
AACTGAAGATCTACAAAAGA (SEQ ID NO: 2);
ACCAAGGTTCTGGAAAGAGA (SEQ ID NO: 3);
TGTAGGTCACCTGAGTGTGA (SEQ ID NO: 4);
GCTGCACCCAGGGGATCCAT (SEQ ID NO: 5);
TCTCGTAGTTGCTTCTGCTG (SEQ ID NO: 6);
GAGCGAGGCCGCAGCGTCTC (SEQ ID NO: 7);
ATCAGCCAGAACCATCACTC (SEQ ID NO: 8);
ACCTGTACCCTATAAGTGGT (SEQ ID NO: 9);
GATAACTTACCTGGAGAGGC (SEQ ID NO: 10);
TTAGGGTTGGACATGATATC (SEQ ID NO: 11);
CCCACTCCTGCAGGGCAGTG (SEQ ID NO: 12);
GGGTCTTCACCACTGGAGAG (SEQ ID NO: 13);
AGTGAAAAGGCTGACCTGAA (SEQ ID NO: 14);
TGGATGCCCGTGACACTGGG (SEQ ID NO: 15);
GCCGGGCCCAGGGGATCCAT (SEQ ID NO: 16);
CACCCAGATCCAGCGTCCCA (SEQ ID NO: 17);
ATCTCCTGACCTTGTGATCC (SEQ ID NO: 18);
GATCTCCTGACCTAGGAAGA (SEQ ID NO: 19);
TTCTCACTCAGTTGGCCCAT (SEQ ID NO: 20);
CCAACCACCACACCTGTCAT (SEQ ID NO: 21);
GGACGAGTAACAGCTGGATT (SEQ ID NO: 22);
GCTTGGCTGCACCCAGGGGATC (SEQ ID NO: 23);
CTCTGCCGCTCCTGGACACTGCTGC (SEQ ID NO: 24);

B3 Cont'd

and continuous 15 or 18 nucleotide fragments of the sequences listed above in an amount effective to treat said cancer.

Please add Claim 22:

B4

22. (New) A method according to claim 9, wherein said olgionucleotide does not activate RNase H.